Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives (Q38193349)

30 August 2017

1 reference

title

Therapeutic drug monitoring in inflammatory bowel disease: current state and future perspectives (English)

1 reference

inflammatory bowel diseases

30 August 2017

main subject

0 references

author

Séverine Vermeire

series ordinal

4

1 reference

30 August 2017

Niels Vande Casteele

1

0 references

William Jeffery Sandborn

series ordinal

6

object named as

William J Sandborn

1 reference

30 August 2017

2

Brian G Feagan

1 reference

30 August 2017

5

Reena Khanna

1 reference

30 August 2017

7

Barrett G Levesque

1 reference

30 August 2017

Ann Gils

3

1 reference

30 August 2017

publication date

1 April 2014

1 reference

Current gastroenterology reports

30 August 2017

published in

1 reference

30 August 2017

volume

16

1 reference

30 August 2017

issue

4

1 reference

30 August 2017

page(s)

378

1 reference

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial

30 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Infliximab for induction and maintenance therapy for ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: Definitions, frequency and pharmacological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Antibody pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Influence of Trough Serum Levels and Immunogenicity on Long-term Outcome of Adalimumab Therapy in Crohn's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Detection of infliximab levels and anti-infliximab antibodies: a comparison of three different assays

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Infliximab trough levels may predict sustained response to infliximab in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Serum adalimumab concentration and clinical remission in patients with Crohn's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Association between pharmacokinetics of adalimumab and mucosal healing in patients with inflammatory bowel diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

A test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Value of drug level testing and antibody assays in optimising biological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Paradoxical inflammation induced by anti-TNF agents in patients with IBD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Early serial trough and antidrug antibody level measurements predict clinical outcome of infliximab and adalimumab treatment: Table 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Antibody Response to Infliximab and its Impact on Pharmacokinetics can be Transient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Addition of an immunomodulator to infliximab therapy eliminates antidrug antibodies in serum and restores clinical response of patients with inflammatory bowel disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

Recent advances: Personalised use of current Crohn's disease therapeutic options

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S11894-014-0378-0

A SPECIAL MEETING REVIEW EDITION: Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2013May 18-21, 2013 • Orlando, FloridaSpecial Reporting on:• Serological and Inflammatory IBD Marker P

21 January 2018

1 reference

12 December 2020

Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.

1 reference

12 December 2020

Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease

1 reference

12 December 2020

Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study

1 reference

12 December 2020

The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic

1 reference

12 December 2020

Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis

1 reference

12 December 2020

Clinical pharmacokinetics of tumor necrosis factor antagonists.

1 reference

12 December 2020

Development and validation of a homogeneous mobility shift assay for the measurement of infliximab and antibodies-to-infliximab levels in patient serum

1 reference

12 December 2020

Individualised therapy is more cost-effective than dose intensification in patients with Crohn's disease who lose response to anti-TNF treatment: a randomised, controlled trial

1 reference

12 December 2020

Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease

1 reference

12 December 2020

10.1007/S11894-014-0378-0

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1008212345

0 references

1 reference